Nucleic Acids for Molecular Diagnosis Industry Research Report 2025
Summary
According to APO Research, The global Nucleic Acids for Molecular Diagnosis market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Nucleic Acids for Molecular Diagnosis include Agilent Technologies, Inc., Aji Bio-Pharma, Bio-synthesis Inc., Danaher Corporation, Eurofins Scientific SE, Integrated DNA Technologies, Kaneka Eurogentec S.A., L.G.C Biosearch Technologies and Merck KGaA, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Acids for Molecular Diagnosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acids for Molecular Diagnosis.
The Nucleic Acids for Molecular Diagnosis market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nucleic Acids for Molecular Diagnosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Nucleic Acids for Molecular Diagnosis Segment by Company
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Acids for Molecular Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nucleic Acids for Molecular Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleic Acids for Molecular Diagnosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nucleic Acids for Molecular Diagnosis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
According to APO Research, The global Nucleic Acids for Molecular Diagnosis market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Nucleic Acids for Molecular Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Nucleic Acids for Molecular Diagnosis include Agilent Technologies, Inc., Aji Bio-Pharma, Bio-synthesis Inc., Danaher Corporation, Eurofins Scientific SE, Integrated DNA Technologies, Kaneka Eurogentec S.A., L.G.C Biosearch Technologies and Merck KGaA, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Acids for Molecular Diagnosis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acids for Molecular Diagnosis.
The Nucleic Acids for Molecular Diagnosis market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nucleic Acids for Molecular Diagnosis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Nucleic Acids for Molecular Diagnosis Segment by Company
- Agilent Technologies, Inc.
- Aji Bio-Pharma
- Bio-synthesis Inc.
- Danaher Corporation
- Eurofins Scientific SE
- Integrated DNA Technologies
- Kaneka Eurogentec S.A.
- L.G.C Biosearch Technologies
- Merck KGaA
- metabion
- QIAGEN
- Thermo Fisher Scientific Inc.
- Hongene
- Synthgene
- DNA Series
- RNA Series
- Early Cancer Screening
- Genetic Diseases
- Blood Screening
- Genome Sequencing
- Infectious Diseases
- Other
- Early Cancer Screening
- Genetic Diseases
- Blood Screening
- Genome Sequencing
- Infectious Diseases
- Other
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Russia
- Netherlands
- Nordic Countries
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- Taiwan
- Southeast Asia
- South America
- Brazil
- Argentina
- Chile
- Middle East & Africa
- Saudi Arabia
- Israel
- United Arab Emirates
- Turkey
- Iran
- Egypt
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Acids for Molecular Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nucleic Acids for Molecular Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleic Acids for Molecular Diagnosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nucleic Acids for Molecular Diagnosis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
1 PREFACE
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Nucleic Acids for Molecular Diagnosis by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 DNA Series
2.2.3 RNA Series
2.3 Nucleic Acids for Molecular Diagnosis by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Early Cancer Screening
2.3.3 Genetic Diseases
2.3.4 Blood Screening
2.3.5 Genome Sequencing
2.3.6 Infectious Diseases
2.3.7 Other
2.4 Assumptions and Limitations
3 NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS BREAKDOWN DATA BY TYPE
3.1 Global Nucleic Acids for Molecular Diagnosis Historic Market Size by Type (2020-2025)
3.2 Global Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Type (2026-2031)
4 NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS BREAKDOWN DATA BY APPLICATION
4.1 Global Nucleic Acids for Molecular Diagnosis Historic Market Size by Application (2020-2025)
4.2 Global Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Application (2026-2031)
5 GLOBAL GROWTH TRENDS
5.1 Global Nucleic Acids for Molecular Diagnosis Market Perspective (2020-2031)
5.2 Global Nucleic Acids for Molecular Diagnosis Growth Trends by Region
5.2.1 Global Nucleic Acids for Molecular Diagnosis Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Nucleic Acids for Molecular Diagnosis Historic Market Size by Region (2020-2025)
5.2.3 Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Region (2026-2031)
5.3 Nucleic Acids for Molecular Diagnosis Market Dynamics
5.3.1 Nucleic Acids for Molecular Diagnosis Industry Trends
5.3.2 Nucleic Acids for Molecular Diagnosis Market Drivers
5.3.3 Nucleic Acids for Molecular Diagnosis Market Challenges
5.3.4 Nucleic Acids for Molecular Diagnosis Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Nucleic Acids for Molecular Diagnosis Players by Revenue
6.1.1 Global Top Nucleic Acids for Molecular Diagnosis Players by Revenue (2020-2025)
6.1.2 Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Players (2020-2025)
6.2 Global Nucleic Acids for Molecular Diagnosis Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Nucleic Acids for Molecular Diagnosis Head Office and Area Served
6.4 Global Nucleic Acids for Molecular Diagnosis Players, Product Type & Application
6.5 Global Nucleic Acids for Molecular Diagnosis Manufacturers Established Date
6.6 Global Nucleic Acids for Molecular Diagnosis Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
7.2 North America Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
7.4 North America Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 EUROPE
8.1 Europe Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
8.2 Europe Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
8.4 Europe Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
9.2 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
9.4 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 SOUTH AMERICA
10.1 South America Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
10.2 South America Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
10.4 South America Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
11.2 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
11.4 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 PLAYERS PROFILED
12.1 Agilent Technologies, Inc.
12.1.1 Agilent Technologies, Inc. Company Information
12.1.2 Agilent Technologies, Inc. Business Overview
12.1.3 Agilent Technologies, Inc. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.1.4 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.1.5 Agilent Technologies, Inc. Recent Developments
12.2 Aji Bio-Pharma
12.2.1 Aji Bio-Pharma Company Information
12.2.2 Aji Bio-Pharma Business Overview
12.2.3 Aji Bio-Pharma Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.2.4 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Product Portfolio
12.2.5 Aji Bio-Pharma Recent Developments
12.3 Bio-synthesis Inc.
12.3.1 Bio-synthesis Inc. Company Information
12.3.2 Bio-synthesis Inc. Business Overview
12.3.3 Bio-synthesis Inc. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.3.4 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.3.5 Bio-synthesis Inc. Recent Developments
12.4 Danaher Corporation
12.4.1 Danaher Corporation Company Information
12.4.2 Danaher Corporation Business Overview
12.4.3 Danaher Corporation Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.4.4 Danaher Corporation Nucleic Acids for Molecular Diagnosis Product Portfolio
12.4.5 Danaher Corporation Recent Developments
12.5 Eurofins Scientific SE
12.5.1 Eurofins Scientific SE Company Information
12.5.2 Eurofins Scientific SE Business Overview
12.5.3 Eurofins Scientific SE Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.5.4 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Product Portfolio
12.5.5 Eurofins Scientific SE Recent Developments
12.6 Integrated DNA Technologies
12.6.1 Integrated DNA Technologies Company Information
12.6.2 Integrated DNA Technologies Business Overview
12.6.3 Integrated DNA Technologies Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.6.4 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio
12.6.5 Integrated DNA Technologies Recent Developments
12.7 Kaneka Eurogentec S.A.
12.7.1 Kaneka Eurogentec S.A. Company Information
12.7.2 Kaneka Eurogentec S.A. Business Overview
12.7.3 Kaneka Eurogentec S.A. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.7.4 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.7.5 Kaneka Eurogentec S.A. Recent Developments
12.8 L.G.C Biosearch Technologies
12.8.1 L.G.C Biosearch Technologies Company Information
12.8.2 L.G.C Biosearch Technologies Business Overview
12.8.3 L.G.C Biosearch Technologies Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.8.4 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio
12.8.5 L.G.C Biosearch Technologies Recent Developments
12.9 Merck KGaA
12.9.1 Merck KGaA Company Information
12.9.2 Merck KGaA Business Overview
12.9.3 Merck KGaA Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.9.4 Merck KGaA Nucleic Acids for Molecular Diagnosis Product Portfolio
12.9.5 Merck KGaA Recent Developments
12.10 metabion
12.10.1 metabion Company Information
12.10.2 metabion Business Overview
12.10.3 metabion Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.10.4 metabion Nucleic Acids for Molecular Diagnosis Product Portfolio
12.10.5 metabion Recent Developments
12.11 QIAGEN
12.11.1 QIAGEN Company Information
12.11.2 QIAGEN Business Overview
12.11.3 QIAGEN Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.11.4 QIAGEN Nucleic Acids for Molecular Diagnosis Product Portfolio
12.11.5 QIAGEN Recent Developments
12.12 Thermo Fisher Scientific Inc.
12.12.1 Thermo Fisher Scientific Inc. Company Information
12.12.2 Thermo Fisher Scientific Inc. Business Overview
12.12.3 Thermo Fisher Scientific Inc. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.12.4 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.12.5 Thermo Fisher Scientific Inc. Recent Developments
12.13 Hongene
12.13.1 Hongene Company Information
12.13.2 Hongene Business Overview
12.13.3 Hongene Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.13.4 Hongene Nucleic Acids for Molecular Diagnosis Product Portfolio
12.13.5 Hongene Recent Developments
12.14 Synthgene
12.14.1 Synthgene Company Information
12.14.2 Synthgene Business Overview
12.14.3 Synthgene Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.14.4 Synthgene Nucleic Acids for Molecular Diagnosis Product Portfolio
12.14.5 Synthgene Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 MARKET OVERVIEW
2.1 Product Definition
2.2 Nucleic Acids for Molecular Diagnosis by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 DNA Series
2.2.3 RNA Series
2.3 Nucleic Acids for Molecular Diagnosis by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Early Cancer Screening
2.3.3 Genetic Diseases
2.3.4 Blood Screening
2.3.5 Genome Sequencing
2.3.6 Infectious Diseases
2.3.7 Other
2.4 Assumptions and Limitations
3 NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS BREAKDOWN DATA BY TYPE
3.1 Global Nucleic Acids for Molecular Diagnosis Historic Market Size by Type (2020-2025)
3.2 Global Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Type (2026-2031)
4 NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS BREAKDOWN DATA BY APPLICATION
4.1 Global Nucleic Acids for Molecular Diagnosis Historic Market Size by Application (2020-2025)
4.2 Global Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Application (2026-2031)
5 GLOBAL GROWTH TRENDS
5.1 Global Nucleic Acids for Molecular Diagnosis Market Perspective (2020-2031)
5.2 Global Nucleic Acids for Molecular Diagnosis Growth Trends by Region
5.2.1 Global Nucleic Acids for Molecular Diagnosis Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Nucleic Acids for Molecular Diagnosis Historic Market Size by Region (2020-2025)
5.2.3 Nucleic Acids for Molecular Diagnosis Forecasted Market Size by Region (2026-2031)
5.3 Nucleic Acids for Molecular Diagnosis Market Dynamics
5.3.1 Nucleic Acids for Molecular Diagnosis Industry Trends
5.3.2 Nucleic Acids for Molecular Diagnosis Market Drivers
5.3.3 Nucleic Acids for Molecular Diagnosis Market Challenges
5.3.4 Nucleic Acids for Molecular Diagnosis Market Restraints
6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS
6.1 Global Top Nucleic Acids for Molecular Diagnosis Players by Revenue
6.1.1 Global Top Nucleic Acids for Molecular Diagnosis Players by Revenue (2020-2025)
6.1.2 Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Players (2020-2025)
6.2 Global Nucleic Acids for Molecular Diagnosis Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Nucleic Acids for Molecular Diagnosis Head Office and Area Served
6.4 Global Nucleic Acids for Molecular Diagnosis Players, Product Type & Application
6.5 Global Nucleic Acids for Molecular Diagnosis Manufacturers Established Date
6.6 Global Nucleic Acids for Molecular Diagnosis Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 NORTH AMERICA
7.1 North America Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
7.2 North America Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
7.4 North America Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 EUROPE
8.1 Europe Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
8.2 Europe Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
8.4 Europe Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 ASIA-PACIFIC
9.1 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
9.2 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
9.4 Asia-Pacific Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 SOUTH AMERICA
10.1 South America Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
10.2 South America Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
10.4 South America Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size (2020-2031)
11.2 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size by Country (2020-2025)
11.4 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 PLAYERS PROFILED
12.1 Agilent Technologies, Inc.
12.1.1 Agilent Technologies, Inc. Company Information
12.1.2 Agilent Technologies, Inc. Business Overview
12.1.3 Agilent Technologies, Inc. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.1.4 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.1.5 Agilent Technologies, Inc. Recent Developments
12.2 Aji Bio-Pharma
12.2.1 Aji Bio-Pharma Company Information
12.2.2 Aji Bio-Pharma Business Overview
12.2.3 Aji Bio-Pharma Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.2.4 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Product Portfolio
12.2.5 Aji Bio-Pharma Recent Developments
12.3 Bio-synthesis Inc.
12.3.1 Bio-synthesis Inc. Company Information
12.3.2 Bio-synthesis Inc. Business Overview
12.3.3 Bio-synthesis Inc. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.3.4 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.3.5 Bio-synthesis Inc. Recent Developments
12.4 Danaher Corporation
12.4.1 Danaher Corporation Company Information
12.4.2 Danaher Corporation Business Overview
12.4.3 Danaher Corporation Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.4.4 Danaher Corporation Nucleic Acids for Molecular Diagnosis Product Portfolio
12.4.5 Danaher Corporation Recent Developments
12.5 Eurofins Scientific SE
12.5.1 Eurofins Scientific SE Company Information
12.5.2 Eurofins Scientific SE Business Overview
12.5.3 Eurofins Scientific SE Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.5.4 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Product Portfolio
12.5.5 Eurofins Scientific SE Recent Developments
12.6 Integrated DNA Technologies
12.6.1 Integrated DNA Technologies Company Information
12.6.2 Integrated DNA Technologies Business Overview
12.6.3 Integrated DNA Technologies Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.6.4 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio
12.6.5 Integrated DNA Technologies Recent Developments
12.7 Kaneka Eurogentec S.A.
12.7.1 Kaneka Eurogentec S.A. Company Information
12.7.2 Kaneka Eurogentec S.A. Business Overview
12.7.3 Kaneka Eurogentec S.A. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.7.4 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.7.5 Kaneka Eurogentec S.A. Recent Developments
12.8 L.G.C Biosearch Technologies
12.8.1 L.G.C Biosearch Technologies Company Information
12.8.2 L.G.C Biosearch Technologies Business Overview
12.8.3 L.G.C Biosearch Technologies Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.8.4 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Product Portfolio
12.8.5 L.G.C Biosearch Technologies Recent Developments
12.9 Merck KGaA
12.9.1 Merck KGaA Company Information
12.9.2 Merck KGaA Business Overview
12.9.3 Merck KGaA Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.9.4 Merck KGaA Nucleic Acids for Molecular Diagnosis Product Portfolio
12.9.5 Merck KGaA Recent Developments
12.10 metabion
12.10.1 metabion Company Information
12.10.2 metabion Business Overview
12.10.3 metabion Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.10.4 metabion Nucleic Acids for Molecular Diagnosis Product Portfolio
12.10.5 metabion Recent Developments
12.11 QIAGEN
12.11.1 QIAGEN Company Information
12.11.2 QIAGEN Business Overview
12.11.3 QIAGEN Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.11.4 QIAGEN Nucleic Acids for Molecular Diagnosis Product Portfolio
12.11.5 QIAGEN Recent Developments
12.12 Thermo Fisher Scientific Inc.
12.12.1 Thermo Fisher Scientific Inc. Company Information
12.12.2 Thermo Fisher Scientific Inc. Business Overview
12.12.3 Thermo Fisher Scientific Inc. Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.12.4 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Product Portfolio
12.12.5 Thermo Fisher Scientific Inc. Recent Developments
12.13 Hongene
12.13.1 Hongene Company Information
12.13.2 Hongene Business Overview
12.13.3 Hongene Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.13.4 Hongene Nucleic Acids for Molecular Diagnosis Product Portfolio
12.13.5 Hongene Recent Developments
12.14 Synthgene
12.14.1 Synthgene Company Information
12.14.2 Synthgene Business Overview
12.14.3 Synthgene Revenue in Nucleic Acids for Molecular Diagnosis Business (2020-2025)
12.14.4 Synthgene Nucleic Acids for Molecular Diagnosis Product Portfolio
12.14.5 Synthgene Recent Developments
13 REPORT CONCLUSION
14 DISCLAIMER
